Related Experiment Videos
Lung cancer vaccines and gene therapy
Kristen M Hege1, David P Carbone
1Cell Genesys, Inc., 500 Forbes Blvd., South San Francisco, CA 94080, USA. kristen.hege@cellgenesys.com
Abstract:
A number of cancer vaccine and gene therapy approaches are being evaluated in patients with lung cancer. Cancer vaccine strategies include GM-CSF gene-modified cancer cells, liposomal MUC1 peptide, anti-idiotype antibody targeting GD3, Mage-3 peptide, and mutant p53 pulsed dendritic cells among others. Preliminary human trials have demonstrated immune responses as well as tumor regression in late stage disease. The largest human gene therapy experience in lung cancer is with intratumoral gene replacement therapy, predominantly with p53, but such approaches are limited to locoregional disease control. Earlier stage gene therapy programs targeting the immune system or tumor vasculature hold promise as systemic therapies for treatment of advanced, disseminated disease.
Insights
Cancer vaccines and gene therapies show promise for lung cancer, with early trials indicating immune responses and tumor regression. Gene therapy for lung cancer is evolving from local treatments to systemic approaches for advanced disease.
Area of Science:
- Oncology
- Immunotherapy
- Gene Therapy
Background:
- Lung cancer treatment is actively exploring novel immunotherapeutic and gene therapy strategies.
- Various cancer vaccine approaches are under investigation, including modified cells, peptides, and dendritic cells.
Purpose of the Study:
- To review current cancer vaccine and gene therapy approaches for lung cancer.
- To assess the potential of these therapies in clinical trials for advanced lung cancer.
Main Methods:
- Review of preliminary human trials for lung cancer vaccines.
- Analysis of gene therapy strategies, including gene replacement and immune-targeting approaches.
Main Results:
- Preliminary trials show immune responses and tumor regression in advanced lung cancer patients.
- Intratumoral gene replacement therapy, mainly with p53, offers locoregional control.
- Gene therapy targeting the immune system or tumor vasculature shows potential for systemic treatment.
Conclusions:
- Cancer vaccines and gene therapies are promising avenues for lung cancer treatment.
- Gene therapy is advancing towards systemic treatments for disseminated lung cancer.
- Further research is needed to optimize these therapies for improved patient outcomes.